BRAF and tumor of duodenum: Genomic mutation assays for KRAS, NRAS, and BRAF were also carried out using biopsy specimens taken from recurrent duodenal tumors, as autopsy specimens were inadequate for this purpose due to the passage of time from patient death to fixation with formalin; mutation at codon 61 of KRAS was identified despite prechemotherapeutic negativity.